About Eloxx Pharmaceuticals Inc
- Industry: Pharmaceuticals
- Exchange: OTC MARKETS
- Country: US
- Website: https://www.eloxxpharma.com/
Frequently Asked Questions
What is the 52-week range for ELOX?
The 52-week high is $23.3999 and the 52-week low is $0.
What is the P/E ratio for ELOX?
The P/E ratio data is currently unavailable.
What is the dividend yield for ELOX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -256.75%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -3862.50%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.72.
Analyst Recommendation Trends
Wall Street analyst consensus for ELOX over the last few months:
Latest ELOX News
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Kodiak Sciences (NASDAQ:KOD) shares increased by 57.4% to $50.93 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY) stock moved
Leerink Partners Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $32
Leerink Partners analyst Joseph Schwartz initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $32.
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced that the first two patients have been dosed in the EXACT Study, a Phase 2b clinical trial evaluating exaluren in patients with nonsense mutation Alport syndrome (NMAS).
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-10 | Domicilium Real Estate Fund III LP | +361,578 | - | - |
| 2026-06-10 | Domicilium Real Estate Fund III LP | +238,422 | - | - |
| 2026-06-10 | Domicilium Real Estate Fund III LP | +361,578 | - | - |
| 2026-06-10 | Domicilium Real Estate Fund III LP | +238,422 | - | - |
| 2026-06-10 | Aggarwal Sumit | +328,833 | - | - |
| 2026-06-08 | Webster Stephen W | +13,587 | - | - |
| 2026-06-08 | Walts Alan Edmund | +8,590 | - | - |
| 2026-06-08 | Kjellson Nina S | +13,587 | - | - |
| 2026-06-08 | Rubin Steven D | +4,018 | - | - |
| 2026-05-27 | Domicilium Real Estate Fund III LP | +113,636 | - | - |
| 2026-05-27 | Domicilium Real Estate Fund III LP | -113,636 | - | - |
| 2026-05-27 | Coastlands Capital LP | +1,250,000 | - | - |
| 2026-05-27 | Coastlands Capital LP | -1,250,000 | - | - |
| 2026-02-28 | Aggarwal Sumit | -260,946 | - | - |
| 2026-02-28 | Aggarwal Sumit | +260,946 | $0.15 | $39,142 |
| 2026-01-24 | Rubin Steven D | -1,875 | - | - |
| 2026-01-24 | Rubin Steven D | +1,875 | - | - |
| 2026-01-24 | Aggarwal Sumit | -15,000 | - | - |
| 2026-01-24 | Aggarwal Sumit | +15,000 | - | - |
| 2026-01-24 | Walts Alan Edmund | -1,875 | - | - |
| 2026-01-24 | Walts Alan Edmund | +1,875 | - | - |